Drug-induced Inflammation in Patients on TNFα Inhibitors

REFERENCES

• Cunningham ET Jr, Wender JD. Practical approach to the use of corticosteroids in patients with uveitis. Can J Ophthalmol. 2010;45(4):352–358.
   Google Scholar
• Taylor SR, Isa H, Joshi L, Lightman S. New developments in corticosteroid therapy for uveitis. Ophthalmologica. 2010;224 (Suppl 1):46–53.
   PubMed Web of Science ®Google Scholar
• Lee FF, Foster CS. Pharmacotherapy for uveitis. Expert Opin Pharmacother 2010;11(7):1135–1146.
   PubMedGoogle Scholar
• Okada AA. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm. 2005;13(5):335–351.
   PubMed Web of Science ®Google Scholar
• Jabs DA. Treatment of ocular inflammation. Ocul Immunol Inflamm. 2004;12(3):163–168.
   PubMedGoogle Scholar
• Lustig MJ, Cunningham ET Jr. Use of immunosuppressive agents in uveitis. Curr Opin Ophthalmol. 2003;14(6):399–412.
   PubMedGoogle Scholar
• Smith JR, Rosenbaum JT. Management of immune mediated uveitis. BioDrugs. 2000;13(1):9–20.
   PubMedGoogle Scholar
• Solomon SD, Cunningham ET Jr. Use of corticosteroids and non-corticosteroid immunosuppressive agents in patients with uveitis. Comp Ophthal Update. 2000;1(5):273–286.
   Google Scholar
• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492–513.
   PubMed Web of Science ®Google Scholar
• Pato E, Muñoz-Fernández S, Francisco F, et al. Uveitis Working Group from Spanish Society of Rheumatology. Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis. Semin Arthritis Rheum. 2011;40(4):314–323.
   Google Scholar
• Rosenbaum JT. Future of biological therapy for uveitis. Curr Opin Ophthalmol. 2010;21(6):473–477.
   PubMed Web of Science ®Google Scholar
• Hemmati HD, Dunn JP. Biologic therapy for uveitis. Expert Rev Ophthalmol. 2010;5(2):225–239.
   Google Scholar
• Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol. 2007;18(6):481–486.
   PubMed Web of Science ®Google Scholar
• Lim L, Suhler EB, Smith JR. Biologic therapies for inflammatory eye disease. Clin Exp Ophthalmol. 2006;34:365–374
   PubMed Web of Science ®Google Scholar
• Sharma SM, Nestel AR, Lee RWJ, Dick AD. Clinical review: anti-TNF- α therapies in uveitis: perspective on 5 years of clinical experience. Ocul Immunol Inflamm. 2009;17(6):403–414.
   PubMed Web of Science ®Google Scholar
• Deuter CME, Kotter I, Wallace GR, Murray PI, Stubiger N, Zierhut M. Behçet’s disease: ocular effects and treatment. Prog Ret Eye Res. 2008;27:111–136.
   PubMed Web of Science ®Google Scholar
• Lee RWJ, Dick AD. Treat early and embrace the evidence in favour of anti-TNF-α therapy for Behçet’s uveitis. Br J Ophthalmol. 2010;94(3):269–270.
   Google Scholar
• Qian Y, Acharya NR. Juvenile idiopathic arthritis-associated uveitis. Curr Opin Ophthalmol. 2010;21(6):468–472.
   Google Scholar
• Cordero-Coma M, Salom D, Díaz-Llopis M, López-Prats MJ, Calleja S. Golimumab for uveitis. Ophthalmology. 2011; 118(9): 1892.e3-4.
   Google Scholar
• Tlucek PS, Stone DU. Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis. Cornea. 2011; Sep 20. [Epub ahead of print]
   Google Scholar
• Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun. 2010;11:180–210.
   PubMedGoogle Scholar
• Goldstein DA. Uncovering the risk of immunosuppressive therapy in patients with uveitis. Arch Ophthalmol. 2009; 127(6):799–800.
   PubMedGoogle Scholar
• Cunningham ET Jr, Zierhut M. TNF inhibitors for uveitis: balancing efficacy and safety. Ocul Immunol Inflamm. 2010;18(6):421–423.
   Google Scholar
• Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007;56(10):3248–3252.
   PubMedGoogle Scholar
• Fonollosa A, Artaraz J, Les I, et al. Sarcoid intermediate uveitis following etanercept treatment: a case report and review of the literature. Ocul Immunol Inflamm. 2012;20(1):44–48.
   Google Scholar
• Seve P, Varron L, Broussolle C, Denis P, Kodjikian L. Sarcoid-related uveitis occurring during adalimumab therapy. Ocul Immunol Inflamm. 2012;20(1):59–60.
   Google Scholar
• Daïen CI, Monnier A, Claudepierre P, et al; Club Rhumatismes et Inflammation (CRI). Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford). 2009;48(8):883–886.
   Google Scholar
• Toussirot E, Pertuiset E. TNFalpha blocking agents and sarcoidosis: an update. Rev Med Interne. 2010;31:828–837.
   PubMed Web of Science ®Google Scholar
• Massara A, Cavazzini L, La Corte R, Trotta F. Sarcoidosis appearing during anti-tumor necrosis factor α therapy: a new “class effect” paradoxical phenomenon. Two case reports and literature review. Semin Arthritis Rheum. 2010;39:313–319.
   PubMed Web of Science ®Google Scholar
• Roux CH, Brocq O, Leccia N, et al. New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect? J Rheumatol. 2007;34:434–437.
   PubMed Web of Science ®Google Scholar
• Palucka AK, Blanck JP, Bennett I, Pascual V, Banchereau J. Cross regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci U S A. 2005;102:3372–3377.
   PubMed Web of Science ®Google Scholar
• Ladoyanni E, Nambi R. Psoriasis exacerbated by interferon-alpha in a patient with chronic myeloid leukemia. J Drugs Dermatol. 2005;4:221–222.
   PubMedGoogle Scholar
• Lee YB, Lee JI, Park HJ, Cho BK, Oh ST. Interferon-alpha induced sarcoidosis with cutaneous involvement along the lines of venous drainage. Ann Dermatol. 2011;23(2):239–241.
   Google Scholar
• Doycheva D, Deuter C, Stuebiger N, Zierhut M. Interferon-alpha-associated presumed ocular sarcoidosis. Graefes Arch Clin Exp Ophthalmol. 2009;247(5):675–680. [Epub 2008 Nov 26]
   Google Scholar
• Viguier M, Richette P, Bachelez H, Wendling D, Aubin F. Paradoxical adverse effects of anti-TNF-a treatment: onset or exacerbation of cutaneous disorders. Expert Rev Clin Immunol. 2009;5(4):421–431.
   Google Scholar
• Levine D, Switlyk SA, Gottlieb A, Cutaneous lupus erythematosus and anti-TNF-α therapy: a case report and review of the literature. J Drugs Derm. 2010;9(10):1283–1287.
   Google Scholar
• Cullen G, Kroshinsky D, Cheifetz AS, Korenik JR. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011 Sep 29. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Akahoshi M, Ishihara M, Remus N, et al. Association between IFNA genotype and the risk of sarcoidosis. Hum Genet. 2004;114:503–509.
   PubMedGoogle Scholar
• Zampino MR, Corazza M, Borghi A, Marzola A, Virgili A. HLA typing in an IFN-alpha-induced scar sarcoidosis: possible pathogenetic and clinical implications. Acta Derm Venereol. 2009;89:661–662.
   Google Scholar
• Moorthy RS, Valluri S, Jampol LM. Drug-induced uveitis. Surv Ophthalmol. 1998;42(6):557–570.
   Google Scholar
• Moorthy RS, Valluri S. Ocular toxicity associated with systemic drug therapy. Curr Opin Ophthalmol. 1999;10(6):438–446.
   PubMedGoogle Scholar
• Fraunfelder FW. Drug-induced ocular inflammatory diseases. Drugs Today (Barc). 2007; 43(2):117–123.
   Google Scholar
• Jabbarpoor Bonyadi MH, Soheilian R, Soheilian M. Topiramate-induced bilateral anterior uveitis associated with hypopyon formation. Ocul Immunol Inflamm. 2011;19(1):86–88.
   Google Scholar
• Fraunfelder FW, Suhler EB, Fraunfelder FT. Hepatitis B vaccine and uveitis: an emerging hypothesis suggested by review of 32 case reports. Cutan Ocul Toxicol. 2010; 29(1):26–29.
   Google Scholar
• Wefers Bettink-Remeijer M, Brouwers K, van Langenhove L, et al. Uveitis-like syndrome and iris transillumination after the use of oral moxifloxacin. Eye (Lond). 2009;23(12):2260–2262.
   PubMed Web of Science ®Google Scholar
• Willermain F, Deflorenne C, Bouffioux C, Janssens X, Koch P, Caspers L. Uveitis-like syndrome and iris transillumination after the use of oral moxifloxacin. Eye (Lond). 2010;24(8):1419.
   PubMed Web of Science ®Google Scholar
• Hinkle DM, Dacey MS, Mandelcorn E, et al. Bilateral uveitis associated with fluoroquinolone therapy. Cutan Ocul Toxicol. 2011 Oct 8. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar